Our study proved that FOXP3+ Tregs can be used as an important prognostic marker for prediction of breast cancer survival outcomes and can also be used as a therapeutic target to improve immunotherapy for breast cancer as blocking the migration or function of Tregs may aid in overcoming human cancers. The gene discussed is FOXP3; the disease is breast carcinoma.